NCT02900664 - A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | Biotech Hunter

Enrollment

283

Participants

Timeline

Start Date

August 23, 2016

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Interventions

BIOLOGICAL

PDR001

Powder for solution for infusion

BIOLOGICAL

ACZ885

Solution for injection

BIOLOGICAL

CJM112

Solution for infusion

DRUG

TMT212

Tablets

DRUG

EGF816

Tablets

Trial Locations (23)

2610

Novartis Investigative Site, Wilrijk

20089

Novartis Investigative Site, Rozzano

20132

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

28050

Novartis Investigative Site, Madrid

31059

Novartis Investigative Site, Toulouse

33305

Novartis Investigative Site, Taoyuan District

37203

Sarah Cannon Research Institute, Nashville

69373

Novartis Investigative Site, Lyon

70403

Novartis Investigative Site, Tainan City

75231

Novartis Investigative Site, Paris

77030

University of Texas MD Anderson Cancer Center, Houston

94800

Novartis Investigative Site, Villejuif

119228

Novartis Investigative Site, Singapore

169610

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

21287-0013

Sidney Kimmel Comprehensive Cancer Center SC-3, Baltimore

02215

Dana Farber Cancer Center, Boston

BE-B-1200

Novartis Investigative Site, Brussels

M5G 2M9

Novartis Investigative Site, Toronto

H3T 1E2

Novartis Investigative Site, Montreal

08036

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat